BioNxt Solutions Inc. XPHYF
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- —
- High
- —
News
1 year ago accessnewswire.com
BioNxt Solutions Announces Closing of Shares for Debt Settlement
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of…
1 year ago accessnewswire.com
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is pleased to announce the receipt of the Semaglutide…
1 year ago accessnewswire.com
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:XPHYF)(FSE:4XT), a bioscience innovator specializing in advanced drug delivery…
1 year ago accessnewswire.com
Bionxt Solutions Provides Bi-Weekly MCTO Status Report
VANCOUVER, BC / ACCESS Newswire / May 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT), announces that, further to its news release dated May 1, 2025…
2 years ago accesswire.com
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company")…
3 years ago accesswire.com
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / October 27, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company")…
3 years ago accesswire.com
BioNxt Solutions Announces Change of Directors
VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as…
4 years ago proactiveinvestors.com
XPhyto Therapeutics says director and founder Professor Dr Raimar Loebenberg receives leadership award from Canadian Society for Pharmaceutical Science
XPhyto Therapeutics Corp has announced that its director and founder Professor Dr Raimar Loebenberg is the 2022 recipient of the Canadian Society for Pharmaceutical Sciences (CSPS) Award of…
4 years ago proactiveinvestors.com
XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head
XPhyto Therapeutics Corp has announced that Dr Florian A. Sahr, a German-born and internationally-trained leader in drug formulation, technology transfer and new-product manufacturing, has joined its…
4 years ago proactiveinvestors.com
XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year
XPhyto Therapeutics Corp has updated on the progress of its Rotigotine transdermal (TDS) patch product candidate, which is a non-ergoline dopamine agonist approved to treat Parkinson's disease (PD)…
4 years ago proactiveinvestors.com
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laboratories Inc's psychedelic medicine programs in…
4 years ago proactiveinvestors.com
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in coming days as the group reported on progress at its…
4 years ago proactiveinvestors.com
XPhyto Therapeutics realizing 'significant synergies' after integration of 3a-diagnostics GmbH
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that its successful integration of 3a-diagnostics GmbH (3a), an acquisition, which closed in December last year, was already bearing…
4 years ago proactiveinvestors.com
XPhyto Therapeutics announces appointment of Drahoslav Zdarek as the company's head of sales, Europe
XPhyto Therapeutics Corp has announced the appointment of Drahoslav Zdarek as the company's head of sales, Europe. The company said Zdarek will focus on building out distribution, sales and marketing…
4 years ago proactiveinvestors.com
Xphyto Therapeutics makes key appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19
Xphyto Therapeutics Corp. said it has made two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the…
4 years ago proactiveinvestors.com
Xphyto Therapeutics makes appointments as it progresses its biosensor and diagnostic products including for the detection of COVID-19
Xphyto Therapeutics Corp said it has made two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the…
4 years ago proactiveinvestors.com
XPhyto progressing its scientific approach to cannabis-based medicine and helping in the coronavirus fight
German subsidiary, Vektor Pharma has developed an oral disintegrating film (ODF) for drug delivery Developed low-cost oral screening test to concurrently detect COVID-19 and non-COVID-19…
4 years ago proactiveinvestors.com
XPhyto epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) provided an update on the development of its fast-dissolving CBD oral strips, noting that its European human CBD bioavailability study will start in…
4 years ago proactiveinvestors.com
XPhyto Therapeutics completes strategic acquisition of 3a-diagnostics GmbH
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) revealed that its acquisition of biotechnology company 3a-diagnostics GmbH (3a), first announced on July 20, 2021, is now complete. "The strategic…
4 years ago proactiveinvestors.com
XPhyto Therapeutics closes its private placements for gross proceeds of C$7M
XPhyto Therapeutics Corp said it has completed its non-brokered private placement as well as its previously-announced non-brokered convertible debenture unit offering, raising total gross proceeds of…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday